ELTP · Elite Pharmaceuticals Inc /Nv/
$0.29
-0.01 (-2.00%)
At close · Aug 24
Market Cap
$323.14M
Shares
1.08B
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.29
Open$0.30
Day$0.29–0.30
52W close$0.29–0.71
Avg vol 30d690K
Short int2.7M · 0.2% float · 3.7d
Short vol19%
Last earningsAug 14, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 13, 2026
Est · unconfirmed
· in 11 wks
FQ2-27 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.9 · calm
Equity put/call 0.68
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−30%
below
Price vs 50-day avg
−20%
below
RSI (14)
20
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−26%
trailing
6-month return
−24%
trailing
YTD return
−41%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.25% of float · ▲ +3.3% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 5-yr low, contrarian setup
Squeeze score
41
elevated · 0–100
Fundamentals
Revenue growth
+41%
Y/Y
Gross margin
296%
expanding
Free cash flow
$22.8M
Valuation
P/E 6
below peers
Balance sheet
$6.8M
net cash
Quant / Vol
risk profile
Volatility
57%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−30%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
20
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.25% of float · ▲ +3.3% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 5-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $1
vs 200-day avg -30%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELTP
this stock
Elite Pharmaceuticals Inc /Nv/
|
$323.14M | -41.0% | +41.0% | 6.0 | 0.2% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.25B | +17.0% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.91B | +2.5% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.98B | +0.5% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
1
- % held
- 0.0%
- Net QoQ
- +500 sh
- Top holder
- KELLEHER FINANCIAL ADVISO…
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELTP | -6.7% | -25.9% | -23.9% | -23.9% | -41.0% |
| SPY | -1.2% | +3.3% | +12.2% | +2.2% | +12.0% |
| vs SPY | -5.6% | -29.2% | -36.1% | -26.1% | -53.0% |